|
US6358932B1
(en)
|
1994-05-31 |
2002-03-19 |
Isis Pharmaceticals, Inc. |
Antisense oligonucleotide inhibition of raf gene expression
|
|
US6391636B1
(en)
|
1994-05-31 |
2002-05-21 |
Isis Pharmaceuticals, Inc. |
Antisense oligonucleotide modulation of raf gene expression
|
|
US6037136A
(en)
|
1994-10-24 |
2000-03-14 |
Cold Spring Harbor Laboratory |
Interactions between RaF proto-oncogenes and CDC25 phosphatases, and uses related thereto
|
|
US5717100A
(en)
|
1995-10-06 |
1998-02-10 |
Merck & Co., Inc. |
Substituted imidazoles having anti-cancer and cytokine inhibitory activity
|
|
AR012634A1
(es)
|
1997-05-02 |
2000-11-08 |
Sugen Inc |
Compuesto basado en quinazolina, composicion famaceutica que lo comprende, metodo para sintetizarlo, su uso, metodos de modulacion de la funcion deserina/treonina proteinaquinasa con dicho compuesto y metodo in vitro para identificar compuestos que modulan dicha funcion
|
|
US6514977B1
(en)
|
1997-05-22 |
2003-02-04 |
G.D. Searle & Company |
Substituted pyrazoles as p38 kinase inhibitors
|
|
JP2002508754A
(ja)
|
1997-05-22 |
2002-03-19 |
ジー ディ サール アンド カンパニ |
ｐ３８キナーゼ阻害剤としての置換基を有するピラゾール類
|
|
GB9716557D0
(en)
|
1997-08-06 |
1997-10-08 |
Glaxo Group Ltd |
Benzylidene-1,3-dihydro-indol-2-one derivatives having anti-cancer activity
|
|
US6022884A
(en)
|
1997-11-07 |
2000-02-08 |
Amgen Inc. |
Substituted pyridine compounds and methods of use
|
|
US6204467B1
(en)
|
1998-03-24 |
2001-03-20 |
Ford Global Technologies, Inc. |
Method and apparatus for resistive welding
|
|
US7351834B1
(en)
|
1999-01-13 |
2008-04-01 |
Bayer Pharmaceuticals Corporation |
ω-Carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
|
|
US6316435B2
(en)
|
1999-02-24 |
2001-11-13 |
Supergen, Inc. |
Combination therapy for lymphoproliferative diseases
|
|
PE20020354A1
(es)
|
2000-09-01 |
2002-06-12 |
Novartis Ag |
Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda)
|
|
DE60224299T2
(de)
|
2001-10-25 |
2008-12-11 |
Novartis Ag |
Kombinationsmedikationen mit einem selektiven cyclooxygenase-2-inhibitor
|
|
EP1456180B1
(en)
|
2001-12-21 |
2007-10-03 |
Vernalis (Cambridge) Limited |
3-(2,4)dihydroxyphenyl-4-phenylpyrazoles and their medical use
|
|
US20080085902A1
(en)
|
2003-09-23 |
2008-04-10 |
Guido Bold |
Combination Of A Vegf Receptor Inhibitor Or With A Chemotherapeutic Agent
|
|
DK1692113T3
(en)
|
2003-11-14 |
2018-01-08 |
Lorus Therapeutics Inc |
ARYLIMIDAZOLES AND USE THEREOF AS ANTICANCES
|
|
EP1706400A1
(en)
|
2004-01-09 |
2006-10-04 |
Novartis AG |
Phenyl- 4-(3-phenyl-1h-pyrazol-4-yl)-pyrimidin-2-yl -amine derivatives as igf-ir inhibitors
|
|
ES2396135T3
(es)
|
2004-06-10 |
2013-02-19 |
Irm Llc |
Compuestos y composiciones como inhibidores de proteínas cinasas
|
|
CA2601766A1
(en)
|
2005-03-17 |
2006-09-28 |
Novartis Ag |
N- [3- (1-amin0-5, 6, 7, 8-tetrahydro-2 , 4, 4b-triazafluoren-9-yl)-phenyl] benzamides as tyrosine/threonine kinase inhibitors, in particular b-raf kinase
|
|
US20070099856A1
(en)
*
|
2005-05-13 |
2007-05-03 |
Gumerlock Paul H |
Combined treatment with docetaxel and an epidermal growth factor receptor kinase inhibitor using an intermittent dosing regimen
|
|
US7608635B2
(en)
|
2005-08-12 |
2009-10-27 |
Synta Pharmaceuticals Corp. |
Pyrazole compounds that modulate HSP90 activity
|
|
EP1919460A2
(en)
|
2005-08-22 |
2008-05-14 |
Novartis AG |
Pharmaceutical compositions comprising a ph-dependent drug, a ph modifier and a retarding agent
|
|
EP1917258A2
(en)
|
2005-08-26 |
2008-05-07 |
SmithKline Beecham Corporation |
Pyrimidinyl-pyrazole inhibitors of aurora kinases
|
|
TW200804345A
(en)
|
2005-08-30 |
2008-01-16 |
Novartis Ag |
Substituted benzimidazoles and methods of preparation
|
|
CA2643066A1
(en)
|
2006-03-16 |
2007-09-20 |
Pfizer Products Inc. |
Pyrazole compounds
|
|
WO2007115286A2
(en)
|
2006-04-05 |
2007-10-11 |
Novartis Ag. |
Combinations of therapeutic agents for treating cancer
|
|
WO2007123892A2
(en)
|
2006-04-17 |
2007-11-01 |
Arqule Inc. |
Raf inhibitors and their uses
|
|
MX2009003456A
(es)
|
2006-10-02 |
2009-04-14 |
Irm Llc |
Compuestos y composiciones como inhibidores de proteina cinasa.
|
|
CN101522026A
(zh)
|
2006-10-06 |
2009-09-02 |
Irm责任有限公司 |
蛋白激酶抑制剂及其应用方法
|
|
EP2491923A3
(en)
|
2007-02-15 |
2012-12-26 |
Novartis AG |
Combinations of therapeutic agents for treating cancer
|
|
US20090022789A1
(en)
|
2007-07-18 |
2009-01-22 |
Supernus Pharmaceuticals, Inc. |
Enhanced formulations of lamotrigine
|
|
KR20100038119A
(ko)
|
2007-08-01 |
2010-04-12 |
화이자 인코포레이티드 |
피라졸 화합물 및 ｒａｆ 억제제로서 이의 용도
|
|
UA100865C2
(ru)
|
2007-10-19 |
2013-02-11 |
Эбботт Гмбх Унд Ко. Кг |
Твердый дисперсный продукт лекарственных средств на основе n-арилмочевины
|
|
EP2220083B1
(en)
|
2007-11-14 |
2017-07-19 |
Janssen Pharmaceuticals, Inc. |
Imidazo[1,2-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
|
|
BRPI0908906A2
(pt)
|
2008-03-21 |
2019-09-24 |
Novartis Ag |
compostos heterocíclicos e usos dos mesmos
|
|
UA103319C2
(en)
|
2008-05-06 |
2013-10-10 |
Глаксосмитклайн Ллк |
Thiazole- and oxazole-benzene sulfonamide compounds
|
|
PL2324008T3
(pl)
|
2008-07-24 |
2012-09-28 |
Nerviano Medical Sciences Srl |
3,4-diarylopirazole jako inhibitory kinazy białkowej
|
|
AU2009276699A1
(en)
|
2008-07-28 |
2010-02-04 |
Gilead Sciences, Inc. |
Cycloalkylidene and heterocycloalkylidene histone deacetylase inhibitor compounds
|
|
JP5603869B2
(ja)
|
2008-09-29 |
2014-10-08 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
新規化合物
|
|
BR122021018683B1
(pt)
|
2008-10-07 |
2022-11-16 |
Kudos Pharmaceuticals Limited |
Formulação farmacêutica de 4-[3-(4-ciclopropanocarbonil- piperazina-1-carbonil)-4-flúor- benzil]-2h-ftalazin-1-ona, uso de um polímero de matriz, forma de dosagem e método para produzir uma dispersão amorfa sólida
|
|
WO2010056662A1
(en)
|
2008-11-11 |
2010-05-20 |
University Of Washington |
Activated wnt-beta-catenin signaling in melanoma
|
|
WO2010070060A1
(en)
|
2008-12-19 |
2010-06-24 |
Nerviano Medical Sciences S.R.L. |
Bicyclic pyrazoles as protein kinase inhibitors
|
|
AR075180A1
(es)
|
2009-01-29 |
2011-03-16 |
Novartis Ag |
Formulaciones orales solidas de una pirido-pirimidinona
|
|
RU2402602C1
(ru)
|
2009-02-12 |
2010-10-27 |
Государственное учреждение Российский онкологический научный центр им. Н.Н. Блохина РАМН |
КЛЕТОЧНАЯ ЛИНИЯ МЕЛАНОМЫ ЧЕЛОВЕКА mel Rac, ИСПОЛЬЗУЕМАЯ ДЛЯ ПОЛУЧЕНИЯ ПРОТИВООПУХОЛЕВЫХ ВАКЦИН
|
|
WO2010100127A1
(en)
|
2009-03-04 |
2010-09-10 |
Novartis Ag |
Disubstituted imidazole derivatives as modulators of raf kinase
|
|
TWI532484B
(zh)
|
2009-06-08 |
2016-05-11 |
艾伯維有限公司 |
包含凋亡促進劑之固態分散劑
|
|
WO2010145998A1
(en)
|
2009-06-15 |
2010-12-23 |
Nerviano Medical Sciences S.R.L. |
Substituted pyrimidinylpyrrolopyridinone derivatives, process for their preparation and their use as kinase inhibitors
|
|
KR101256018B1
(ko)
|
2009-08-20 |
2013-04-18 |
한국과학기술연구원 |
단백질 키나아제 저해활성을 갖는 1,3,6-치환된 인돌 화합물
|
|
AR077975A1
(es)
|
2009-08-28 |
2011-10-05 |
Irm Llc |
Derivados de pirazol pirimidina y composiciones como inhibidores de cinasa de proteina
|
|
US8242260B2
(en)
|
2009-08-28 |
2012-08-14 |
Novartis Ag |
Compounds and compositions as protein kinase inhibitors
|
|
CN104958294A
(zh)
|
2010-01-27 |
2015-10-07 |
内尔维安诺医学科学有限公司 |
作为蛋白激酶抑制剂的3,4-二芳基吡唑的亚磺酰氨基衍生物
|
|
JP6155187B2
(ja)
|
2010-03-30 |
2017-06-28 |
ヴァーセオン コーポレイション |
トロンビンの阻害剤としての多置換芳香族化合物
|
|
JP5938038B2
(ja)
|
2010-08-03 |
2016-06-22 |
ネルヴィアーノ・メディカル・サイエンシズ・ソチエタ・ア・レスポンサビリタ・リミタータ |
ピラゾロフェニル−ベンゼンスルホンアミド化合物の誘導体及びその抗腫瘍薬としての使用
|
|
DK2688572T3
(en)
|
2011-03-21 |
2017-06-12 |
Valcuria Ab |
PHARMACEUTICAL COMPOSITION WITH AN HDAC INHIBITOR AND A STEROID AND USE THEREOF
|
|
CA2844407A1
(en)
|
2011-06-14 |
2012-12-20 |
Novartis Ag |
Combination of panobinostat and ruxolitinib in the treatment of cancer such as a myeloproliferative neoplasm
|
|
WO2013078264A1
(en)
|
2011-11-23 |
2013-05-30 |
Novartis Ag |
Pharmaceutical formulations
|
|
RU2015121367A
(ru)
|
2012-11-08 |
2017-01-10 |
Новартис Аг |
Фармацевтическая комбинация, содержащая ингибитор b-raf и ингибитор деацетилазы гистонов, и ее применение при лечении пролиферативных заболеваний
|